Mal-PEG3-C1-NHS ester

Cat. No.: HY-133581 Purity: ≥95.0%: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

Mal-PEG3-C1-NHS ester is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

For research use only. We do not sell to patients.

Mal-PEG3-C1-NHS ester Chemical Structure

CAS No. : 2230016-26-7

Size	Stock	Quantity
Solvent
5 mg (260.19 mM * 50 μL in DMSO)	In-stock	Estimated Time of Arrival: December 31
Solvent
10 mg (260.19 mM * 100 μL in DMSO)	In-stock	Estimated Time of Arrival: December 31
Solvent
25 mg (260.19 mM * 250 μL in DMSO)	In-stock	Estimated Time of Arrival: December 31
Solvent
50 mg (260.19 mM * 500 μL in DMSO)	In-stock	Estimated Time of Arrival: December 31

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Linker Isoform Specific Products:

View All Isoforms

Cleavable Linker Non-cleavable Linker Acid Cleavable Linker Disulfide Cleavable Linker Protease Cleavable Linker Glycosidase Cleavable Linker Phosphatase Cleavable Linker

Biological Activity
Purity & Documentation
References
Customer Review

Description	Mal-PEG3-C1-NHS ester is a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)^[1].
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Mal-PEG3-C1-NHS ester Related Antibodies
Molecular Weight	384.34
Formula	C₁₆H₂₀N₂O₉
CAS No.	2230016-26-7
Appearance	Liquid
Color	Colorless to light yellow
SMILES	O=C(ON1C(CCC1=O)=O)COCCOCCOCCN2C(C=CC2=O)=O
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Solution, -20°C, 2 years
Purity & Documentation	Purity: ≥95.0% Select Batch: Data Sheet (265 KB) SDS (393 KB) COA (246 KB) Handling Instructions (2659 KB)
References	[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. [Content Brief]